March 16 (Reuters) - Spyre Therapeutics Inc SYRE.O:
SPYRE ANNOUNCES ACCELERATION OF EXPECTED TOPLINE READOUT OF SKYWAY RHEUMATOID ARTHRITIS SUB-STUDY TO Q3 2026
SPYRE THERAPEUTICS INC - PSA AND AXSPA SUB-STUDY RECRUITMENT ON TRACK; TOPLINE DATA EXPECTED Q4 2026
SPYRE THERAPEUTICS INC - SKYLINE UC TRIAL ENROLLING AHEAD OF SCHEDULE; PART A READOUTS BEGIN Q2 2026